Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.63 |
| ▸ | CNR2 | P34972 | 8/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838956 | 0.93 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL923180 | 0.93 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL12907707 | 0.91 | CNR1 (0.66) | CNR1CNR2KDM4EMEN1MAPT | |
| SCHEMBL4914114 | 0.91 | CNR2 (0.66) | CNR1CNR2 | |
| SCHEMBL4914356 | 0.90 | GABRA2 (0.60) | CNR1CNR2GABRA2GABRB2PPARA | |
| SCHEMBL4612450 | 0.90 | CNR1 (0.67) | CNR1CNR2PPARAKDM4EMEN1 | |
| SCHEMBL662250 | 0.90 | CNR1 (0.65) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL13814761 | 0.89 | CNR2 (0.63) | CNR1CNR2PPARA | |
| SCHEMBL2627954 | 0.89 | CNR1 (0.68) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL2873082 | 0.89 | CNR1 (0.65) | CNR1CNR2KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354442-B2 | Imidazol-4-one and imidazole-4-thione compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-01-15 | — | — | US | disclosed |
| WO-2010062686-A2 | IMIDAZOL-4-ONE AND IMIDAZOLE-4-THIONE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | CNR1, CNR2, HRH4 | CNR1 1/4885CNR2 2/4885GABRA2 353/4885 |
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | CNR1 597/4885CNR2 480/4885GABRA2 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.